It’s been a busy time for pharmaceutical research and development group Argenta Discovery of late; the group has just announced two new alliances in the space of 24 hours.

The firm has entered into a “fee-for-service collaboration” with fellow UK-based group Antisoma plc, under which scientists from both parties will put their heads together to develop improved molecules for the latter’s programme of telomere targeting agents for potential cancer candidates.

Financial terms of the deal were not disclosed, but commenting on the agreement Argenta’s chief, Dr Christopher Ashton, said it “confirms the contract research team’s experience in undertaking integrated, oncology-focused programmes, and underlines Argenta’s ongoing commitment to providing first class contract R&D services to leading organisations in the pharmaceutical industry”.

NeuroSolutions agreement
In line with this last claim, the company went on to announce another new alliance, with NeuroSolutions Ltd, under which it gains “preferential access” to its specialist electrophysiology and hERG testing services and expertise.

The relationship with NeuroSolutions enables Argenta to boost its biochemistry and in vitro screening capabilities, and firm has “a number of contract research programmes in the pipeline for 2008 which will benefit from NeuroSolutions’ support and expertise,” Ashton explained. More specific details on the deal were, however, not revealed.